Bone Biologics Corp BBLG.OQ reported a quarterly adjusted loss of $1.31 per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $-55.20. The lone analyst forecast for the quarter was for a loss of $7.60 per share.
Reported revenue was zero; analysts expected zero.
Bone Biologics Corp's reported EPS for the quarter was a loss of $1.31.
Bone Biologics Corp shares had fallen by 10.8% this quarter and lost 58.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.
In the last 30 days, there have been earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
Wall Street's median 12-month price target for Bone Biologics Corp is $19.50
This summary was machine generated from LSEG data May 15 at 12:05 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING |
ESTIMATE |
ACTUAL |
BEAT, MET, MISSED |
Mar. 31 2024 |
-7.60 |
-1.31 |
Beat |
Dec. 31 2023 |
-5.60 |
-2.47 |
Beat |
Sep. 30 2023 |
-24.32 |
-4.88 |
Beat |
Jun. 30 2023 |
-12.00 |
-3.84 |
Beat |